(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are CUMULEX, UMICORE, and NORTHERN DRILLING.

Financial Asset	Price	Change	Updated (EST)
CUMULEX (CLEX.BR)	2.00	50.38%	2023-10-17 12:05:28
UMICORE (UMI.BR)	25.30	13.96%	2023-10-17 12:21:46
NORTHERN DRILLING (NODL.OL)	3.85	13.24%	2023-10-17 12:41:32
EBUSCO HOLDING (EBUS.AS)	7.87	11.63%	2023-10-17 12:01:37
ARTEA (ARTE.PA)	15.50	9.15%	2023-10-17 12:45:31
BERGENBIO (BGBIO.OL)	0.15	9.04%	2023-10-17 12:24:48
BIOSENIC (BIOS.BR)	0.07	8.52%	2023-10-17 12:05:03
KEYWARE TECH. (KEYW.BR)	0.89	7.93%	2023-10-17 12:20:30
ABIONYX PHARMA (ABNX.PA)	1.32	7.82%	2023-10-17 12:44:28
BELYSSE GROUP (BELYS.BR)	0.73	7%	2023-10-17 12:04:59

The three biggest losers today are SAS AB, PCI BIOTECH HOLD, and NORDIC SEMICONDUC.

Financial Asset	Price	Change	Updated (EST)
SAS AB (SASNO.OL)	0.05	-21.59%	2023-10-17 12:42:40
PCI BIOTECH HOLD (PCIB.OL)	2.30	-20.69%	2023-10-17 12:42:03
NORDIC SEMICONDUC (NOD.OL)	93.92	-19.03%	2023-10-17 12:41:26
CELYAD ONCOLOGY (CYAD.BR)	0.69	-8.97%	2023-10-17 12:05:15
AUGROS COSMETICS (AUGR.PA)	6.65	-6.99%	2023-10-17 12:45:45
FUT.CLUBE PORTO (FCP.LS)	1.12	-6.67%	2023-10-17 12:23:06
TOMTOM (TOM2.AS)	5.61	-6.34%	2023-10-17 12:03:59
IDEX BIOMETRICS (IDEX.OL)	0.48	-6.31%	2023-10-17 12:40:33
ATOS (ATO.PA)	4.87	-5.58%	2023-10-17 12:45:41
KBC (KBC.BR)	54.22	-4.74%	2023-10-17 12:20:26

Winners today

1. CUMULEX (CLEX.BR)

50.38% Price Change

Cumulex N.V. does not have significant operations. Previously, the company was engaged in sugar plantation business in the Democratic Republic of Congo. The company was formerly known as Sucrerie et Raffinerie de l'Afrique Centrale NV and changed its name to Cumulex N.V. in March 2021. The company was founded in 1956 and is based in Diegem, Belgium. Cumulex N.V. is a subsidiary of Value8 NV.

BEL 20 ended the session with CUMULEX rising 50.38% to €2.00 on Tuesday, after five sequential sessions in a row of losses. BEL 20 fell 0.01% to €3,517.95, following the last session’s upward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, CUMULEX has a trailing twelve months EPS of €-0.23.

Volatility

CUMULEX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 68.42%, a negative 68.42%, and a positive 28.74%.

CUMULEX’s highest amplitude of average volatility was 68.42% (last week), 68.42% (last month), and 28.74% (last quarter).

More news about CUMULEX.

2. UMICORE (UMI.BR)

13.96% Price Change

Umicore SA operates as a materials technology and recycling company worldwide. It operates through Catalysis, Energy & Surface Technologies, and Recycling segments. The Catalysis segment produces automotive catalysts for gasoline, and diesel light and heavy-duty diesel applications; stationary catalysis for industrial emissions control; and precious metals-based compounds and catalysts for use in the pharmaceutical and fine chemicals industries, as well as fuel cell applications. The Energy & Surface Technologies segment offers cobalt and specialty materials, rechargeable battery materials, and electro-optic materials, as well as metal deposition solutions, including electroplating and PVD coating. The Recycling segment treats waste streams containing precious and other specialty metals from a range of industrial residues and end-of-life materials. This segment also produces precious metals-based materials for glass production, electric, and electronic applications. The company was formerly known as Union Minière du Haut Katanga and changed its name to Umicore SA in 2001. Umicore SA was founded in 1805 and is headquartered in Brussels, Belgium.

BEL 20 ended the session with UMICORE rising 13.96% to €25.30 on Tuesday, after two sequential sessions in a row of gains. BEL 20 fell 0.01% to €3,517.95, following the last session’s upward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, UMICORE has a trailing twelve months EPS of €2.02.

PE Ratio

UMICORE has a trailing twelve months price to earnings ratio of 12.52. Meaning, the purchaser of the share is investing €12.52 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.58%.

More news about UMICORE.

3. NORTHERN DRILLING (NODL.OL)

13.24% Price Change

Northern Drilling Ltd. operates as an offshore drilling contractor to the oil and gas industry. The company primarily engages in acquiring and operating offshore drilling assets, as well as involved in drilling in ultra-deep water environments. Northern Drilling Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.

Oslo Børs Benchmark Index_GI ended the session with NORTHERN DRILLING jumping 13.24% to €3.85 on Tuesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI slid 0.17% to €1,309.81, after three consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-5.47.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.22%.

Yearly Top and Bottom Value

NORTHERN DRILLING’s stock is valued at kr3.85 at 22:40 EST, way below its 52-week high of kr34.90 and way above its 52-week low of kr2.05.

More news about NORTHERN DRILLING.

4. EBUSCO HOLDING (EBUS.AS)

11.63% Price Change

Ebusco Holding N.V., together with its subsidiaries, develops, manufactures, and distributes zero emission buses, batteries, and charging systems in the Netherlands, Belgium, France, Germany, Norway, Switzerland, and Denmark. It also sells ancillary products and services; and provides electric vehicle ecosystem repair and maintenance services. Ebusco Holding N.V. was founded in 2010 and is headquartered in Deurne, the Netherlands.

AEX-Index ended the session with EBUSCO HOLDING jumping 11.63% to €7.87 on Tuesday, after five successive sessions in a row of gains. AEX-Index rose 0.19% to €736.77, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, EBUSCO HOLDING has a trailing twelve months EPS of €-1.11.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.25%.

Yearly Top and Bottom Value

EBUSCO HOLDING’s stock is valued at €7.87 at 22:40 EST, way below its 52-week high of €17.70 and way above its 52-week low of €4.21.

Volume

Today’s last reported volume for EBUSCO HOLDING is 893622 which is 411.47% above its average volume of 174715.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12.5%, now sitting on 116.25M for the twelve trailing months.

Volatility

EBUSCO HOLDING’s last week, last month’s, and last quarter’s current intraday variation average was 10.47%, 1.40%, and 3.19%.

EBUSCO HOLDING’s highest amplitude of average volatility was 10.47% (last week), 4.66% (last month), and 3.19% (last quarter).

More news about EBUSCO HOLDING.

5. ARTEA (ARTE.PA)

9.15% Price Change

Artea SA operates as a real estate development company in France. It develops tertiary parks, emblematic projects, urban office buildings, eco-neighborhoods, hotels, shops, and housing projects. The company also generates and supplies electrical power using renewable sources, such as photovoltaics and hydraulics. Artea SA was founded in 2001 and is headquartered in Paris, France.

CAC 40 ended the session with ARTEA jumping 9.15% to €15.50 on Tuesday, after two successive sessions in a row of gains. CAC 40 rose 0.11% to €7,029.70, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, ARTEA has a trailing twelve months EPS of €1.47.

PE Ratio

ARTEA has a trailing twelve months price to earnings ratio of 10.54. Meaning, the purchaser of the share is investing €10.54 for every euro of annual earnings.

Volatility

ARTEA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.72%, a negative 3.31%, and a positive 2.56%.

ARTEA’s highest amplitude of average volatility was 1.20% (last week), 4.66% (last month), and 2.56% (last quarter).

Volume

Today’s last reported volume for ARTEA is 607 which is 405.83% above its average volume of 120.

More news about ARTEA.

6. BERGENBIO (BGBIO.OL)

9.04% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO jumping 9.04% to €0.15 on Tuesday while Oslo Børs Benchmark Index_GI dropped 0.17% to €1,309.81.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-1.83.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.

Moving Average

BERGENBIO’s value is way higher than its 50-day moving average of kr0.13 and way under its 200-day moving average of kr4.18.

Volatility

BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was 3.85%, 0.94%, and 5.15%.

BERGENBIO’s highest amplitude of average volatility was 9.32% (last week), 4.34% (last month), and 5.15% (last quarter).

Volume

Today’s last reported volume for BERGENBIO is 116733000 which is 212.14% above its average volume of 37397400.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BERGENBIO’s stock is considered to be oversold (<=20).

More news about BERGENBIO.

7. BIOSENIC (BIOS.BR)

8.52% Price Change

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with BIOSENIC jumping 8.52% to €0.07 on Tuesday while BEL 20 slid 0.01% to €3,517.95.

Earnings Per Share

As for profitability, BIOSENIC has a trailing twelve months EPS of €5.34.

PE Ratio

BIOSENIC has a trailing twelve months price to earnings ratio of 0.01. Meaning, the purchaser of the share is investing €0.01 for every euro of annual earnings.

Volatility

BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 11.18%, a positive 4.29%, and a positive 8.55%.

BIOSENIC’s highest amplitude of average volatility was 12.59% (last week), 12.95% (last month), and 8.55% (last quarter).

More news about BIOSENIC.

8. KEYWARE TECH. (KEYW.BR)

7.93% Price Change

Keyware Technologies NV, an independent fintech company, provides electronic payment solutions in Belgium. It offers payment transaction software for banks and financial institutions, tokenization software, instalment payment solutions, and ordering and payment app software; and payment processing and management services, as well as rents and sells payment terminals. The company was incorporated in 1996 and is headquartered in Zaventem, Belgium.

BEL 20 ended the session with KEYWARE TECH. jumping 7.93% to €0.89 on Tuesday, after two sequential sessions in a row of losses. BEL 20 dropped 0.01% to €3,517.95, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, KEYWARE TECH. has a trailing twelve months EPS of €0.05.

PE Ratio

KEYWARE TECH. has a trailing twelve months price to earnings ratio of 17.7. Meaning, the purchaser of the share is investing €17.7 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.71%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 27.9%, now sitting on 23.97M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, KEYWARE TECH.’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for KEYWARE TECH. is 985 which is 64.29% below its average volume of 2759.

Moving Average

KEYWARE TECH.’s value is under its 50-day moving average of €0.90 and below its 200-day moving average of €0.96.

More news about KEYWARE TECH..

9. ABIONYX PHARMA (ABNX.PA)

7.82% Price Change

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.

CAC 40 ended the session with ABIONYX PHARMA rising 7.82% to €1.32 on Tuesday, following the last session’s upward trend. CAC 40 jumped 0.11% to €7,029.70, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, ABIONYX PHARMA has a trailing twelve months EPS of €-0.15.

Revenue Growth

Year-on-year quarterly revenue growth grew by 312%, now sitting on 5.3M for the twelve trailing months.

Moving Average

ABIONYX PHARMA’s worth is higher than its 50-day moving average of €1.28 and way below its 200-day moving average of €1.74.

Yearly Top and Bottom Value

ABIONYX PHARMA’s stock is valued at €1.32 at 22:40 EST, way below its 52-week high of €2.49 and way above its 52-week low of €1.11.

More news about ABIONYX PHARMA.

10. BELYSSE GROUP (BELYS.BR)

7% Price Change

Belysse Group NV produces and sells textile floor coverings for commercial and residential applications in Europe, North America, and internationally. The company designs, manufactures, and distributes broadloom carpets and modular carpet tiles primarily for offices and public projects. It commercializes its products under the Bentley, modulyss, arc edition, and ITC brands. The company was formerly known as Balta Group NV and changed its name to Belysse Group NV in October 2022. Belysse Group NV was founded in 1964 and is headquartered in Waregem, Belgium. Belysse Group NV is a subsidiary of LSF9 Belysse Holdco S.à r.l.

BEL 20 ended the session with BELYSSE GROUP rising 7% to €0.73 on Tuesday, after four successive sessions in a row of losses. BEL 20 dropped 0.01% to €3,517.95, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, BELYSSE GROUP has a trailing twelve months EPS of €-0.44.

Volume

Today’s last reported volume for BELYSSE GROUP is 1250 which is 78.51% below its average volume of 5817.

More news about BELYSSE GROUP.

Losers Today

1. SAS AB (SASNO.OL)

-21.59% Price Change

SAS AB (publ), together with its subsidiaries, provides passenger flight transportation services in the Nordic and international route network. The company also offers air cargo services, in-flight sales, ground handling, and technical maintenance services, as well as travel-related loyalty programs. It operates a fleet of 135 aircraft, including 12 long-haul aircraft, 95 short-haul aircraft, and 28 aircraft flown by regional production partners. The company was founded in 1946 and is headquartered in Stockholm, Sweden. On July 5, 2022, SAS AB (publ), along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Oslo Børs Benchmark Index_GI ended the session with SAS AB falling 21.59% to €0.05 on Tuesday, after five sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI slid 0.17% to €1,309.81, after three consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, SAS AB has a trailing twelve months EPS of kr-0.8.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SAS AB’s EBITDA is 0.85.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SAS AB’s stock is considered to be oversold (<=20).

Volatility

SAS AB’s last week, last month’s, and last quarter’s current intraday variation average was a positive 12.71%, a negative 1.38%, and a positive 4.01%.

SAS AB’s highest amplitude of average volatility was 12.71% (last week), 9.39% (last month), and 4.01% (last quarter).

More news about SAS AB.

2. PCI BIOTECH HOLD (PCIB.OL)

-20.69% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD sliding 20.69% to €2.30 on Tuesday, after four sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI slid 0.17% to €1,309.81, after three consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.68.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be oversold (<=20).

Earnings Before Interest, Taxes, Depreciation, and Amortization

PCI BIOTECH HOLD’s EBITDA is -4.54.

More news about PCI BIOTECH HOLD.

3. NORDIC SEMICONDUC (NOD.OL)

-19.03% Price Change

Nordic Semiconductor ASA, a fabless semiconductor company, designs, sells, and delivers integrated circuits (ICs) and related products and services for use in short- and long- range wireless applications in Europe, the Americas, and the Asia/Pacific. The company offers bluetooth and multiprotocol Systems-on-Chip (SoCs) that provides short-range connectivity; and Systems-in-Package (SiPs), which offers connectivity on long-range LTE-M and NB-IoT cellular networks. It also provides nRF9160 SiP low power cellular IoT device, nRF Cloud solution, nRF Connect software development kit, and third-party cellular modules; DECT NR+, a non-cellular radio standard; nRF7002 Wi-Fi companion ICs; and nRF52840 and nRF5340 multiprotocol SoCs. In addition, the company offers Bluetooth mesh; Bluetooth direction finding solution; Bluetooth Low Energy SoCs; Bluetooth LE audio products; Matter, a Connected Home over IP solution; Thread, an IP-based wireless networking protocol solution; Zigbee products; ANT solutions, including wireless multiprotocol SoCs supporting the ANT wireless protocol; pre-certified development modules and modems; and range extenders. Further, it provides built-in power management on SoCs and dedicated power management ICs comprising nPM1100 PMIC, nPM1300 PMIC, nPM6001 PMIC, nPM1100 EK, and Power Profiler Kit II; Device-to-nRF Cloud and Cloud-to-nRF Cloud solutions; and application specific integrated circuits and related consulting services. The company's products are used in various applications, such as automotive, beacon, computer peripherals, connected health, connected home, education, industrial automation, LED lighting, logistics and transport, retail and payment, sports and fitness, toys and gaming, virtual reality and augmented reality products, and wearables. Nordic Semiconductor ASA was founded in 1983 and is headquartered in Trondheim, Norway.

Oslo Børs Benchmark Index_GI ended the session with NORDIC SEMICONDUC falling 19.03% to €93.92 on Tuesday while Oslo Børs Benchmark Index_GI dropped 0.17% to €1,309.81.

Earnings Per Share

As for profitability, NORDIC SEMICONDUC has a trailing twelve months EPS of kr4.19.

PE Ratio

NORDIC SEMICONDUC has a trailing twelve months price to earnings ratio of 22.42. Meaning, the purchaser of the share is investing kr22.42 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.15%.

Volume

Today’s last reported volume for NORDIC SEMICONDUC is 3816660 which is 625.18% above its average volume of 526302.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 85.4% and a negative 82.1%, respectively.

More news about NORDIC SEMICONDUC.

4. CELYAD ONCOLOGY (CYAD.BR)

-8.97% Price Change

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with CELYAD ONCOLOGY falling 8.97% to €0.69 on Tuesday while BEL 20 slid 0.01% to €3,517.95.

Earnings Per Share

As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.35.

Volatility

CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was 2.57%, 0.04%, and 6.51%.

CELYAD ONCOLOGY’s highest amplitude of average volatility was 6.79% (last week), 6.78% (last month), and 6.51% (last quarter).

Volume

Today’s last reported volume for CELYAD ONCOLOGY is 21625 which is 53.06% below its average volume of 46070.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CELYAD ONCOLOGY’s stock is considered to be oversold (<=20).

More news about CELYAD ONCOLOGY.

5. AUGROS COSMETICS (AUGR.PA)

-6.99% Price Change

Augros Cosmetic Packaging SA provides customized packaging solutions in France. The company offers decoration solutions for glass, plastic, and aluminum packaging materials. It serves the perfume, cosmetic, and spirit industries. The company is based in Alencon, France. Augros Cosmetic Packaging SA operates as a subsidiary of Famille Bourgine.

CAC 40 ended the session with AUGROS COSMETICS falling 6.99% to €6.65 on Tuesday while CAC 40 rose 0.11% to €7,029.70.

Earnings Per Share

As for profitability, AUGROS COSMETICS has a trailing twelve months EPS of €0.46.

PE Ratio

AUGROS COSMETICS has a trailing twelve months price to earnings ratio of 14.46. Meaning, the purchaser of the share is investing €14.46 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AUGROS COSMETICS’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for AUGROS COSMETICS is 3054 which is 945.89% above its average volume of 292.

More news about AUGROS COSMETICS.

6. FUT.CLUBE PORTO (FCP.LS)

-6.67% Price Change

Futebol Clube do Porto – Futebol, S.A.D., together with its subsidiaries, participates in professional football competitions, and the sporting events promotion and organization in Portugal. It also engages in the image rights commercialization, sponsoring, merchandising, and products licensing activities; production, editing, and commercialization of multimedia material, as well as Internet, periodical, and non-periodical publications; and sport equipment management and exploration business, as well as insurance broking activities. In addition, the company organizes and sells travel and tour packages; and tickets and seat reservations, as well as represents travel agencies and tourism. Further, it is involved in the concept, design, development, production, direction, promotion, marketing, acquisition, exploration rights, recording, distribution, and dissemination of works and audiovisual programs, multimedia, television, video, cinema, theme, Internet, channels, tourist events, and cultural and sporting in any formats and systems. Additionally, the company manages, operates, and provides services in the areas of recording, production, and communication of audiovisual works, television shows, sounds, images, and other audiovisuals; and edits periodic publicities, books, and multimedia. It also explores for the Porto Canal cable television channel; and produces and executes advertisings, news reports, documentaries, and TV programs in video support. The company was founded in 1893 and is headquartered in Porto, Portugal.

PSI ended the session with FUT.CLUBE PORTO dropping 6.67% to €1.12 on Tuesday while PSI rose 0.45% to €6,144.03.

Earnings Per Share

As for profitability, FUT.CLUBE PORTO has a trailing twelve months EPS of €0.98.

PE Ratio

FUT.CLUBE PORTO has a trailing twelve months price to earnings ratio of 1.14. Meaning, the purchaser of the share is investing €1.14 for every euro of annual earnings.

More news about FUT.CLUBE PORTO.

7. TOMTOM (TOM2.AS)

-6.34% Price Change

TomTom N.V. develops and sells navigation and location-based products and services worldwide. The company operates in two segments, Location Technology and Consumer. It offers standard definition, advanced driver assistance system (ADAS), high definition (HD) maps, and map data, as well as places for map products; traffic and travel information products, including real-time traffic, hazard warning, speed camera, speed profile, fuel and weather services, electric vehicle (EV) and parking services, and routing; and navigation products, such as navigation engine, traffic and travel information, navigation user interface, EV routing and range, and maps for automotive. The company also provides AutoStream, a solution that enables fast and efficient map delivery of the TomTom automated driving (AD) and ADAS Maps; RoadCheck, a tool for carmakers to determine when, where, and under what conditions their vehicles can safely activate AD functions; TomTom indigo, a digital cockpit platform; and virtual horizon products. In addition, it offers road analytics solutions, including traffic stats, origin destination analysis, route monitoring, road event reporter, and junction analytics; and navigation devices, accessories, and map updates, as well as support services. The company serves the automotive, and fleet management and logistics industries. TomTom N.V. was founded in 1991 and is headquartered in Amsterdam, the Netherlands.

AEX-Index ended the session with TOMTOM dropping 6.34% to €5.61 on Tuesday, after two sequential sessions in a row of losses. AEX-Index jumped 0.19% to €736.77, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, TOMTOM has a trailing twelve months EPS of €-0.19.

More news about TOMTOM.

8. IDEX BIOMETRICS (IDEX.OL)

-6.31% Price Change

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless financial payment, access control, and smart cards, as well as card-based devices for the storage of digital currencies. It primarily serves manufacturers of smart cards for financial payment applications and biometric payment card markets. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with IDEX BIOMETRICS falling 6.31% to €0.48 on Tuesday while Oslo Børs Benchmark Index_GI fell 0.17% to €1,309.81.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-0.26.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -141.4%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

IDEX BIOMETRICS’s EBITDA is -124.75.

Volatility

IDEX BIOMETRICS’s last week, last month’s, and last quarter’s current intraday variation average was a positive 5.70%, a negative 0.27%, and a positive 3.16%.

IDEX BIOMETRICS’s highest amplitude of average volatility was 5.70% (last week), 3.90% (last month), and 3.16% (last quarter).

More news about IDEX BIOMETRICS.

9. ATOS (ATO.PA)

-5.58% Price Change

Atos SE provides digital transformation solutions and services worldwide. It offers advanced computing solutions; analytics, artificial intelligence, and automation solutions; cloud solutions; customer journey analytics and digital customer experience; decarbonization solutions; digital consulting; digital workplace solutions; edge computing and Internet of things solutions; and modern applications and platforms. The company also provides advance detection and response, data protection and governance, digital workplace security, IoT and OT security, trusted digital identities, and cybersecurity solutions; and infrastructure and foundation services. It serves financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, resources and services, telecom, media, and entertainment industries. The company was incorporated in 1982 and is headquartered in Bezons, France.

CAC 40 ended the session with ATOS dropping 5.58% to €4.87 on Tuesday while CAC 40 rose 0.11% to €7,029.70.

Earnings Per Share

As for profitability, ATOS has a trailing twelve months EPS of €-10.01.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATOS’s stock is considered to be oversold (<=20).

Volatility

ATOS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.39%, a negative 1.62%, and a positive 3.46%.

ATOS’s highest amplitude of average volatility was 3.28% (last week), 3.53% (last month), and 3.46% (last quarter).

More news about ATOS.

10. KBC (KBC.BR)

-4.74% Price Change

KBC Group NV, together with its subsidiaries, provides integrated bank-insurance services primarily for retail, private banking, small and medium sized enterprises, and mid-cap clients. The company offers demand deposits and savings accounts; home and mortgage loans; consumer finance and SME funding services; credit, investment fund and asset management, and life and non-life insurance; and cash management, payments, trade finance, lease, money market, capital market products, and stockbroking services. It also provides digital and mobile banking services. The company was formerly known as KBC Bank and Insurance Holding Company NV and changed its name to KBC Group NV in March 2005. KBC Group NV was incorporated in 1935 and is headquartered in Brussels, Belgium.

BEL 20 ended the session with KBC falling 4.74% to €54.22 on Tuesday while BEL 20 slid 0.01% to €3,517.95.

Earnings Per Share

As for profitability, KBC has a trailing twelve months EPS of €7.64.

PE Ratio

KBC has a trailing twelve months price to earnings ratio of 7.1. Meaning, the purchaser of the share is investing €7.1 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.09%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.3%, now sitting on 9.09B for the twelve trailing months.

Yearly Top and Bottom Value

KBC’s stock is valued at €54.22 at 22:40 EST, way under its 52-week high of €72.46 and way above its 52-week low of €48.14.

Volume

Today’s last reported volume for KBC is 557852 which is 1.95% above its average volume of 547168.

More news about KBC.

Stay up to date with our winners and losers daily report